With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

Vertex Pharmaceuticals VRTX announced that the European Commission has approved Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) for treating people with cystic fibrosis (“CF”) aged six years and above ...

The IA showed clinically meaningful, disease-modifying benefits for TRIKAFTA ® /KAFTRIO ®, including a 76% and 70% reduction in the cumulative annual rate of pulmonary exacerbations in the U.S ...

Through the first half of the year, Vertex reported profits of $1.6 billion, with 89% of its revenue coming from Trikafta (marketed as Kaftrio in Europe).

Trikafta/Kaftrio The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are ...

However, higher Trikafta/Kaftrio sales are likely to have caused sales erosion of Vertex’s other CF drugs. While CF remains the main area of focus, the company saw rapid success in its non-CF ...

Strong demand for its triple-combination cystic fibrosis therapy, Trikafta/Kaftrio, delivered $2.45 billion in revenue. Management slightly raised its 2024 revenue guidance by about 1% at the ...

Vertex Pharmaceuticals Incorporated today announced that the European Commission has granted approval for the label expansion of KAFTRIO ® in a combination regimen ...

About KAFTRIO ® (ivacaftor ... TRIKAFTA can cause serious side effects, including: Liver damage and worsening of liver function in patients with severe liver disease that can be serious and may ...

Trikafta/Kaftrio is a triple combination regimen that further expands the eligible patient population by an additional 30,000 patients worldwide. Just since the beginning of 2021, ...